Cinobufacini ameliorates experimental colitis via modulating the composition of gut microbiota
Autoři:
Yongfeng Bai aff001; Siwei Wang aff002; Wenkai Xu aff003; Yuanyuan Weng aff001; Shengmei Zhu aff003; Hao Sheng aff004; Jin Zhu aff001; Feng Zhang aff001
Působiště autorů:
Department of Clinical Laboratory, Quzhou People's Hospital, Quzhou, Zhejiang, China
aff001; Department of Core Facility, Quzhou People's Hospital, Quzhou, Zhejiang, China
aff002; Department of Medical Information and Technology, Quzhou People's Hospital, Quzhou, Zhejiang, China
aff003; Medical School, Zhejiang University, Hangzhou, Zhejiang, China
aff004
Vyšlo v časopise:
PLoS ONE 14(9)
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0223231
Souhrn
Background
Cinobufacini, the sterilized hot water extraction of dried toad skin, has been widely used in the treatment of inflammation and cancers. Recently we found cinobufacini could ameliorate dextran sulfate sodium (DSS)-induced colitis in mice, but the underlying mechanism was not fully understood. In current study, we explored the effect of cinobufacini on gut microbiota in DSS-induced acute colitic mouse model by pyrosequencing of colonic contents.
Methods
C57BL/6 mice were supplied with normal or 3.0% DSS containing drinking water. DSS-treat mice were gavaged daily either with vehicle (water) or cinobufacini (10.0 or 30.0 mg/kg) for 7 days. The composition of the gut microbiota was assessed by analyzing 16S rRNA gene sequences.
Results
Our data indicated that cinobufacini reversed DSS-induced gut dysbiosis and enhanced intestinal barrier integrity. Moreover, changing of some specific microbial groups such as Proteobacteria and Bacteroides was closely correlated with the re-establishment of intestinal equilibrium and the recovery of intestinal function.
Conclusion
Cinobufacini prevents colitis in mice by modifying the composition and function of gut microbiota. The current study provides additional mechanistic insight in the therapeutic effect of cinobufacini treatment and may pave the way for clinical application of cinobufacini in colitis therapy.
Klíčová slova:
Bacteroides – Body weight – Colon – Gastrointestinal tract – Gut bacteria – Inflammation – Inflammatory bowel disease – Colitis
Zdroje
1. Kaplan GG (2015) The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 12: 720–727. doi: 10.1038/nrgastro.2015.150 26323879
2. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ (2015) Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 26: 26191. doi: 10.3402/mehd.v26.26191 25651997
3. Matsuoka K, Kanai T (2015) The gut microbiota and inflammatory bowel disease. Semin Immunopathol 37: 47–55. doi: 10.1007/s00281-014-0454-4 25420450
4. Knights D, Lassen KG, Xavier RJ (2013) Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 62: 1505–1510. doi: 10.1136/gutjnl-2012-303954 24037875
5. Ni J, Wu GD, Albenberg L, Tomov VT (2017) Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol 14: 573–584. doi: 10.1038/nrgastro.2017.88 28743984
6. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, et al. (2018) Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol 11: 1–10. doi: 10.1007/s12328-017-0813-5 29285689
7. Xu J, Chen N, Wu Z, Song Y, Zhang Y, et al. (2018) 5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. Front Microbiol 9: 1274. doi: 10.3389/fmicb.2018.01274 29951050
8. Cui H, Cai Y, Wang L, Jia B, Li J, et al. (2018) Berberine Regulates Treg/Th17 Balance to Treat Ulcerative Colitis Through Modulating the Gut Microbiota in the Colon. Front Pharmacol 9: 571. doi: 10.3389/fphar.2018.00571 29904348
9. McFadden RM, Larmonier CB, Shehab KW, Midura-Kiela M, Ramalingam R, et al. (2015) The Role of Curcumin in Modulating Colonic Microbiota During Colitis and Colon Cancer Prevention. Inflamm Bowel Dis 21: 2483–2494. doi: 10.1097/MIB.0000000000000522 26218141
10. Qi J, Tan CK, Hashimi SM, Zulfiker AH, Good D, et al. (2014) Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agents. Evid Based Complement Alternat Med 2014: 312684. doi: 10.1155/2014/312684 24734105
11. Wang SW, Bai YF, Weng YY, Fan XY, Huang H, et al. (2019) Cinobufacini Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice through Inhibiting M1 Macrophage Polarization. J Pharmacol Exp Ther 368: 391–400. doi: 10.1124/jpet.118.254516 30606760
12. Cunha Filho GA, Schwartz CA, Resck IS, Murta MM, Lemos SS, et al. (2005) Antimicrobial activity of the bufadienolides marinobufagin and telocinobufagin isolated as major components from skin secretion of the toad Bufo rubescens. Toxicon 45: 777–782. doi: 10.1016/j.toxicon.2005.01.017 15804527
13. Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M (2014) Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 104: Unit 15 25.
14. Zhu W, Winter MG, Byndloss MX, Spiga L, Duerkop BA, et al. (2018) Precision editing of the gut microbiota ameliorates colitis. Nature 553: 208–211. doi: 10.1038/nature25172 29323293
15. Kim JJ, Shajib MS, Manocha MM, Khan WI (2012) Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp.
16. Viennois E, Chen F, Laroui H, Baker MT, Merlin D (2013) Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA. BMC Res Notes 6: 360. doi: 10.1186/1756-0500-6-360 24010775
17. Cao G, Wang K, Li Z, Tao F, Xu Y, et al. (2018) Bacillus amyloliquefaciens Ameliorates Dextran Sulfate Sodium-Induced Colitis by Improving Gut Microbial Dysbiosis in Mice Model. Front Microbiol 9: 3260. doi: 10.3389/fmicb.2018.03260 30671050
18. Mao L, Kitani A, Strober W, Fuss IJ (2018) The Role of NLRP3 and IL-1beta in the Pathogenesis of Inflammatory Bowel Disease. Front Immunol 9: 2566. doi: 10.3389/fimmu.2018.02566 30455704
19. Lee SH (2015) Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest Res 13: 11–18. doi: 10.5217/ir.2015.13.1.11 25691839
20. Manichanh C, Borruel N, Casellas F, Guarner F (2012) The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 9: 599–608. doi: 10.1038/nrgastro.2012.152 22907164
21. Mukhopadhya I, Hansen R, El-Omar EM, Hold GL (2012) IBD-what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol 9: 219–230. doi: 10.1038/nrgastro.2012.14 22349170
22. Berkes J, Viswanathan VK, Savkovic SD, Hecht G (2003) Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 52: 439–451. doi: 10.1136/gut.52.3.439 12584232
23. Wexler HM (2007) Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 20: 593–621. doi: 10.1128/CMR.00008-07 17934076
24. Delday M, Mulder I, Logan ET, Grant G (2019) Bacteroides thetaiotaomicron Ameliorates Colon Inflammation in Preclinical Models of Crohn's Disease. Inflamm Bowel Dis 25: 85–96. doi: 10.1093/ibd/izy281 30215718
25. Zhou Y, Zhi F (2016) Lower Level of Bacteroides in the Gut Microbiota Is Associated with Inflammatory Bowel Disease: A Meta-Analysis. Biomed Res Int 2016: 5828959. doi: 10.1155/2016/5828959 27999802
26. Zheng H, Chen M, Li Y, Wang Y, Wei L, et al. (2017) Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine. Front Microbiol 8: 1703. doi: 10.3389/fmicb.2017.01703 28936203
27. Mattos-Graner RO, Duncan MJ (2017) Two-component signal transduction systems in oral bacteria. J Oral Microbiol 9: 1400858. doi: 10.1080/20002297.2017.1400858 29209465
28. Zambetti LP, Mortellaro A (2014) NLRPs, microbiota, and gut homeostasis: unravelling the connection. J Pathol 233: 321–330. doi: 10.1002/path.4357 24740681
29. Atreya I, Atreya R, Neurath MF (2008) NF-kappaB in inflammatory bowel disease. J Intern Med 263: 591–596. doi: 10.1111/j.1365-2796.2008.01953.x 18479258
30. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, et al. (2013) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14: 207–215. doi: 10.1016/j.chom.2013.07.007 23954159
31. Gamallat Y, Meyiah A, Kuugbee ED, Hago AM, Chiwala G, et al. (2016) Lactobacillus rhamnosus induced epithelial cell apoptosis, ameliorates inflammation and prevents colon cancer development in an animal model. Biomed Pharmacother 83: 536–541. doi: 10.1016/j.biopha.2016.07.001 27447122
Článek vyšel v časopise
PLOS One
2019 Číslo 9
- Proč se v Česku šíří několik „vymýcených“ infekcí najednou? Ptáme se odborníků
- ADHD jako evoluční výhoda? Výzkum se zaměřil na lovce a sběrače
- Není migréna jako migréna: Co pociťují ženy a co muži?
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Není statin jako statin aneb praktický přehled rozdílů jednotlivých molekul
Nejčtenější v tomto čísle
- Graviola (Annona muricata) attenuates behavioural alterations and testicular oxidative stress induced by streptozotocin in diabetic rats
- CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer’s disease
- Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections
- Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania
Zvyšte si kvalifikaci online z pohodlí domova
Všechny kurzy